TY  - JOUR 
AU  - Jandu, H.K.
AU  - Veal, C.D.
AU  - Fachal Vilar, Laura
AU  - Luccarini, C.
AU  - Aguado-Barrera, M.E.
AU  - Altabas, M.
AU  - Azria, D.
AU  - Baten, A.
AU  - Bourgier, C.
AU  - Bultijnck, R.
AU  - Colciago, R.R.
AU  - Farcy-Jacquet, M.-P.
AU  - Chang-Claude, J.
AU  - Choudhury, A.
AU  - Dunning, A.
AU  - Elliott, R.M.
AU  - Green, S.
AU  - Gutiérrez-Enríquez, S.
AU  - Herskind, C.
AU  - Lambrecht, M.
AU  - Monten, C.
AU  - Rancati, T.
AU  - Reyes, V.
AU  - Rosenstein, B.S.
AU  - De Ruysscher, D.
AU  - Carmen De Santis, M.
AU  - Seibold, P.
AU  - Sperk, E.
AU  - Veldwijk, M.
AU  - Paul Symonds, R.
AU  - Stobart, H.
AU  - Taboada Valladares, Maria Begoña
AU  - Vega Gliemmo, Ana
AU  - Veldeman, L.
AU  - Webb, A.J.
AU  - Weltens, C.
AU  - West, C.M.
AU  - Rattay, T.
AU  - Talbot, C.J.
PY  - 2023
SN  - 1879-0887
UR  - http://hdl.handle.net/20.500.11940/21533
AB  - Background and purpose: Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be...
LA  - eng
KW  - Humans
KW  - Female
KW  - Breast Neoplasms
KW  - Genome-Wide Association Study
KW  - Cohort Studies
KW  - Prospective Studies
KW  - Radiation Injuries
KW  - Polymorphism, Single Nucleotide
TI  - Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer
DO  - 10.1016/j.radonc.2023.109806
T2  - Radiotherapy and Oncology
KW  - FPGMX
KW  - AS Santiago
KW  - CHUS
KW  - FPGMX
VL  - 187
ER  -